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Abstract 
Eosinophil granule major basic protein (117 residues) is known to contain free sulfhydryl groups. Here we have located in the amino acid sequence 
the half-cystine residues present as cysteine, and identified those engaged in disulfide bridges. Of the 9 half-cystine residues, 5 are unpaired cysteines 
(Cys’, Cys”, Cys4’, Cys”, and Cys%), while 4 form disulfides (Cy~~~-Cys”~, and Cysg2-Cys”‘~. 
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1. Introduction sulthydryl groups, but the number has not been deter- 
mined [10,15,16]. 
Eosinophil leukocytes contain within their granules a 
number of cationic proteins, including major basic pro- 
tein (MBP) [1,2]. MBP is the predominant protein in the 
eosinophil granule [3,4] and forms the core of the granule 
[5,6]. MBP is cytotoxic to mammalian cells [7l and is 
implicated in the tissue damage associated with eosino- 
phi1 irmltration, in particular damage to respiratory epi- 
thelium in asthma [8]. Also, the protein is toxic to para- 
sites and is believed to play a key role in antiparasitic 
defense [9]. 
Curiously, it has been found that in serum of pregnant 
women MBP immunoreactivity rises throughout the pe- 
riod of gestation [17], and it has been shown recently that 
the molecule responsible for this is actually unprocessed 
proMBP [ 181. In pregnancy, the source of proMBP is not 
the eosinophil, but rather placental X-cells [19,20]. 
Here we report the status of the 9 half-cystine residues 
present in mature eosinophil MBP. The results show that 
MBP contains 5 free sulthydryl groups and 2 disulfide 
bridges. 
MBP has a molecular weight of 13.8 kDa and a calcu- 
lated p1 of 10.9 [lo]. From cDNA cloning it is known 
that MBP is synthesized as a larger precursor of 25.2 
kDa (preproMBP) that is cleaved by an unknown mech- 
anism in the cell to yield the mature protein [11,12]. 
While the mature protein is extremely basic, the pro- 
portion is quite acidic with a p1 of 3.9 resulting in a 
near-neutral, putative proMBP molecule (PI = 6.2). It is 
hypothesized, that the pro-part functions to mask toxic- 
ity of mature MBP intracellularly [13]. MBP released 
from the eosinophil into plasma has been shown to bind 
to larger, yet unidentified proteins by disulfide bond for- 
mation [14]. The protein is known to possess reactive 
2. Materials and methods 
2.1. Proteins 
Major basic protein was purified from human eosinophils by isolat- 
ing intact granules from lysed cells and extracting proteins with acid as 
previously described [14,21]. In the absence of reductant MBP slowly 
forms dimers and polymers [15,161. To prevent oxidation of free sulfhy- 
dry1 groups DlT was included in the acidic storage buffer (25 mM 
Na-acetate, 150 mM NaCl, 20 mM D’IT, pH 4.3). The material was 
kept frozen (-80°C) for a few weeks. Porcine pepsin was from 
Worthington, and tosyl-phenylalanine chloromethylketone-treated bo-
vine trypsin was from Cooper Biomedicals. 
2.2. Colwnn materials and chemicals 
*Corresponding author. Fax: (45) (8942) 2679 
Sephadex G-25 SF was purchased from Pharmacia, and Nucleosil 
100-5 Cl8 was from Macherey-Nagel. All standard chemicals were 
purchased from Merck or Sigma. 
2.3. Separation of peptides by RP-HPLC 
Abbreviations: CM, carboxymethyl; DTT, dithiothreitol; GuHCl, gua- 
nidinium chloride; HPLC, high-performance liquid chromatography; 
Peptides resulting from enzymatic degradation were separated on a 
Nucleosil Cl8 column (0.4 x 25 cm) eluted at a flow rate of 1 ml/mm. 
MBP, eosinophil granule major basic protein; PTH, phenylthiohydan- A linear gradient, developed over 70 min, was formed from 0.1% (v/v) 
tion; RP, reversed-phase; TFA, triflouroacetic acid. TFA (A) and 90% (v/v) acetonitrile containing 0.075% (v/v) TFA (B) 
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(&SO% B). The column was operated at 50 “C, and the separation was 
monitored by recording the absorbance at 229 nm. 
2.4. Amino acid analysis 
Amino acid compositions were determined by cation exchange fol- 
lowing hydrolysis at 110 “C for 18 h in sealed evacuated tubes contain- 
ing 6 M HCl, 0.1% phenol, and 5% thioglycollic acid [22]. This system, 
a modification of one previously described [23], allows determination 
of cysteine without derivatization. Analysis was performed using >200 
pm01 material. 
2.5. Sequence analysis 
Edman degradations were performed on an Applied Biosystems 
477A sequencer with an 120 on-line HPLC using a polybrene-coated 
glass filter or ProSpin sample preparation cartridge. Glass filters were 
precycled before sample application. 
2.6. Experimental details 
2.6.1. Alkylation. To remove DTT, 1 ml of MBP (1.8 mg/ml) was 
thawed and desalted on a Sephadex G-25 SF column equilibrated and 
eluted with 25 mM Na-acetate, 150 mM NaCI, pH 4.3. The protein was 
recovered in a tube containing iodoacetic acid (final concentration 400 
mM), and the pH was raised over 20 min; first to 7.0 by adding Tris 
base (1 M), and then to pH 9.0 by addition of NaOH (1 M). As known 
from previous results precipitation of MBP occurs at neutral pH [IO]. 
To clear the solution and to alkylate potentially buried SH-groups, 
GuHCl was added to a final concentration of 6 M, and the solution was 
left for 90 min at room temperature in the dark. Afterwards, the mate- 
rial was dialyzed against 25 mM Na-acetate, 150 mM NaCl, pH 4.3 
(unclear solution), and samples for amino acid and sequence analysis 
were removed. From non-reducing SDS-PAGE (not shown) it was 
estimated that > 95% of MBP was present as the 13.8 kDa alkylated 
monomer. 
2.6.2. Enzymatic digestion. After adjusting the pH to 2.0 by adding 
phosphoric acid, the dialyzed material was digested with pepsin (1:25 
(w/w)) at 37’C for 20 h. The clear solution of peptides was separated 
by RP-HPLC as shown below (Fig. 1). Peptide PCM5 (Table l), dis- 
solved in 100 mM NH4HC03, pH 8.7, was further digested with trypsin 
(I:10 (w/w)) at 37°C for 20 h. 
3. Results 
Major basic protein dissolved in acidic buffer contain- 
ing DTT to preserve the free sulfhydryl groups (as ex- 
plained above) was used as starting material. To prevent 
thiol-disulfide exchange reactions in the protein freed 
from DTT, it was mixed with iodoacetic acid, and the pH 
of the solution slowly increased. GuHCl was then added 
to ensure alkylation of potentially buried SH-groups. 
Alkylated protein was hydrolysed in reducing medium 
and from amino acid analysis the amount of CMCys and 
Cys present was estimated. Relative to 8 residues of leuc- 
ine in MBP, we found 4.8 residues of CMCys and 4.3 
residues of Cys (data not shown), corresponding to 5 
40 * 50 60 
TCRYLLVRSL QTFSQAWFTC RRCYRGNLVS IHNFNINYRI QCSVSALNQG QVWIGGRITG 
* 10 20 * 30 
Table 1 
Half-cystine containing peptides identified in the peptic digest of al- 
kylated MBP (Fig. 1) 
Peptide Sequence” (residue numbers) 
PCMl TERYLL (l-6) 
PCM2 RIQhVAL (39-46) 
PCM3 NQGQVWIGGRITGSGRtRRFQWVDG (48-72) 
PCM4 
PCMSb 
PTRGGY (96-101) 
FTCRRPYRGNL (18-28) 
WAAHQPWSRGGHCVAL (80-95) 
WRRAHCLRRLPFICSY (102-117) 
“Half-cystines marked with an asterisk were unequivocally identified as 
CMCys by amino acid and sequence analysis. 
bathe 3 sequences of PCMS were present in equimolar amounts as seen 
from amino acid and sequence analysis. From reducing hydrolysis the 
amount of Cys present was 4 times that of CMCys corresponding to 
one of the 5 half-cystines being present as CMCys. Sequence analysis 
revealed that either Cys*’ or Cys’07 was not part of a disulfide bridge 
since CMCys was seen in cycle 6. No information on the arrangement 
of the distide bridges could be obtained from sequencing PCMS. 
half-cystines that had been susceptible to modification 
with iodoacetic acid and thus present as Cys, and 4 half- 
cystine residues engaged in disulfide bonds. 
From sequence analysis of the alkylated MBP (28 cy- 
cles) it was found that the half-cystines at position 2 and 
23 were recovered as PTH-CMCys residues, and thus 
had been present as cysteine residues in native MBP In 
contrast, no PTH derivative was found in cycle 20 sug- 
gesting that Cyszo was present in disulfide bridge linkage. 
The alkylated MBP was digested with pepsin and the 
resulting peptides were separated by RP-HPLC as shown 
in Fig. 1. From amino acid and sequence analysis it was 
found that the peptides PCM1-4 contained Cys’, CYSTS, 
CYSU, and CYSTS, respectively, in the form of CMCys as 
shown in Table 1. The peptides shown were recovered in 
yields between 30% and 60%. Besides PCM14 (and 
PCMS discussed below), peptides not containing half- 
cystine corresponding to the rest of MBP were identified 
in comparable yields, and a few peptides that were vari- 
ants of PCM14 were recovered in lower yields (not 
shown). Generally, only peptides in yields higher than 
approx. 5% were considered. 
* 70 80 90 * 100 110 
SGRCRRFQWV DGSRWNFAYW AAHQPWSRGG HCVALCTRGGY WRPAHCLRR LPFICSY 
Fig. 1. Reversed-phase HPLC of peptic digest of alkylated MBP. A 0.4 x 25 cm column packed with Nucleosil Cl8 lo&5 was eluted with a linear 
gradient (....) formed from 0.1% (v/v) TFA (A) and 90% (v/v) acetonitrile containing 0.075% (v/v) TFA (B). One third of the peptic digest (i.e. 0.6 
mg MBP) was loaded, the absorbance was measured at 229 nm, and fractions were collected manually. All fractions were analyzed and peptides 
containing CMCys or Cys, were identified. The peptides shown in Table 1 are pointed out. Only fractions collected within the bar contained Cys, 
as described in the main text. The time scale refers to the gradient. 
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Fig. 2. Reversed-phase HPLC of tryptic digest of peptide PCMS. Identified half-cystine containing peptides hown in Table 2 are pointed out. Peptides 
arising from PCMS were recovered in equimolar yields. The peaks marked a and b were identified as the tryptophan containing peptides WR (102-103) 
and WAAHQPWSR (S&88), respectively. Conditions for separation were as explained in legend to Fig. 1. 
Of the peptides eluting before approx. 47 min from 
start of the gradient (Fig. l), none were identified that 
contained Cys”, CYSTS, CYSTS, Cysio7, or Cysn5. These 
residues were recovered exclusively in fractions collected 
within the bar shown in Fig. 1. Amino acid and sequence 
analysis of the fraction corresponding to the peak 
marked PCMS (Fig. 1) revealed the peptide set shown in 
Table 1. The 3 N-termini were seen in equimolar 
amounts, and CMCys appeared in cycle 6. 
To reveal the arrangement of disuhide bonds in PCM5 
it was digested with trypsin. Besides a variety of peptides 
not containing half-cystine only 3 peptides containing 
either CMCys or Cys were recovered following RP- 
HPLC separation of the digest (Fig. 2). These peptides, 
all eluting as well defined peaks as a result of the specific 
cleavages obtained with trypsin, are shown in Table 2. 
The peptides were unequivocally identified by amino 
acid and sequence analysis. Thus, CYSTS, in agreement 
with the sequence analysis of the undigested material, is 
Table 2 
Half-cystine containing pcptides identified after tryptic digestion of 
PCMS and separation by RP-HPLC (Fig. 2) 
Peptide Sequence’ (residue numbers) 
PTl 6YR (23-25) 
FT2b GGHCVAL (89-95) 
AHCLR (105-109) 
PT3b FTCRR (18-22) 
RLPFICSY (110-117) 
"The half-cystine residue marked with an asterisk was unequivocally 
identified as CMCys by amino acid and sequence analysis. 
bTwo sequences were seen in cquimolar amounts, and bis-PTH-Cys, 
was detected in steps 4 (PT2) and 6 (PT3). 
present as CMCys in alkylated MBP. Furthermore, 
Cys20 and Cys”’ are connected by a disulfide bridge as 
are CYSTS and Cyslo7. 
Also, fractions containing the remaining peaks within 
the bar shown in Fig. 1 were analysed. They were mainly 
variants of PCMS shortened or elongated by one or a few 
residues. From tryptic digests of individual fractions 
only the same disulfide bound peptides and the stretch 
containing CYSTS could be recovered (not shown). 
4. Discussion 
This work presents experimental evidence that human 
eosinophil major basic protein contains 5 free sulfhydryl 
groups (Cys’, CYSTS, Cys”, CyP, and Cys 96) and 2 
disulfide bridges (Cy~~~-Cys”~, and Cy~~~-Cys’~~), as 
summarized in Fig. 3. It was recognized earlier that 
sullhydryl groups are present in the molecule [10,15,16], 
but to what extent had not been resolved. 
During purification, storage, and processing of the 
native protein, it might be expected that thiol-disulfide 
exchange reactions could occur to a limited degree. How- 
ever, all column fractions were analysed, and such poten- 
tial rearrangements were not detected. It cannot be 
excluded that partial reduction has occurred in the pres- 
ence of reductant, but the acidic pH of the storage buffer 
makes this unlikely. Some peptides were recovered as 
several variants due to the use of pepsin. In particular, 
peptide set PCMS (Table 1) was seen in several different 
forms as described above. 
It has been established that MBP is homologous with 
animal lectins, in particular the lectin domain of the 
low-affinity IgE receptor of lymphocytes, FcERII (31% 
identity) [24]. Further, on the basis of this homology it 
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Fig. 3. Complete primary structure of human eosinophil major basic protein. Half-cystine residues bearing free sullhydryl groups are marked with 
an asterisk (Cys’, Cy?, CASKS, CYST, and Cysg6), and the 2 disulfide bridges (Cys”‘-Cys’i5, and Cy~~~-Cys’~~) are shown by lines. 
was suggested that MBP contains 2 disulfide bridges [24], 
those localized in the present work. The 5 half-cystine 
residues in MBP here shown to possess free sulfhydryl 
groups are all unique compared to other members of the 
animal lectin family, exemplified by the structure of 
human pancreatic stone protein and tetranectin [25,26]. 
In contrast to MBP, no other member is believed to 
contain free thiol groups. 
In guinea pig, 2 forms of MBP have been recognized, 
GMBPl and GMBP2 [27]. Comparison with the human 
sequence reveals that the 4 half-cystines engaged in disul- 
fide bond formation are conserved in both guinea pig 
MBP forms. Regarding the unpaired half-cystines of 
human MBP, 4 are conserved in GMBPl (Cysz3, Cys4’, 
Cys? and CYSTS), while 3 are conserved in GMBP2 
(Cys2, CYSTS, and CYSTS). 
The proform of MBP, proMBP, has recently been 
isolated from human pregnancy serum [18]. In preg- 
nancy, the source of proMBP is placental X-cells rather 
than eosinophils [19,201, and the protein found in serum 
is complexed to pregnancy-associated plasma protein-A 
(PAPP-A) [18]. Curiously, proMBP exists as a dimer in 
the complex with PAPP-A, a disulfide bond between the 
2 residues corresponding to Cys2 in MBP being responsi- 
ble in part [18]. In addition, at least one Cys residue in 
the pro-piece of proMBP further links to PAPP-A 
[18,28]. The complete arrangement of disulfide bonds in 
the complex (PAPPNproMBP) is not yet known. 
MBP is unusual among the proteins related to animal 
lectins in having both free thiol groups and disulfide 
bridges. Whether the thiols in MBP play a role for the 
function of MBP as a cytotoxic molecule is not known. 
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